

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Sacco, RL; Roth, GA; Reddy, KS; Arnett, DK; Bonita, R; Gaziano, TA; Heidenreich, PA; Huffman, MD; Mayosi, BM; Mendis, S; +8 more... Murray, CJ; Perel, P; Piñeiro, DJ; Smith, SCJr; Taubert, KA; Wood, DA; Zhao, D; Zoghbi, WA; (2016) The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation. *Circulation*, 133 (23). e674-90. ISSN 0009-7322 DOI: <https://doi.org/10.1161/CIR.0000000000000395>

Downloaded from: <http://researchonline.lshtm.ac.uk/3761888/>

DOI: <https://doi.org/10.1161/CIR.0000000000000395>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

1 **AHA/WHF Scientific Statement**

2 **The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature**  
3 **Deaths From Cardiovascular Diseases and Stroke: A Modeling Study**

4 Ralph L. Sacco, MD, MS; Gregory A. Roth, MD, MPH; K. Srinath Reddy, MD, DM; Donna K. Arnett,  
5 PhD, MSPH; Ruth Bonita, PhD; Thomas A. Gaziano, MD; Paul A. Heidenreich, MD, MS; Mark D.  
6 Huffman, MD, MPH; Bongani M. Mayosi, MBChB, DPhil; Shanthi Mendis, MD; Christopher J.L.  
7 Murray, MD, DPhil; Pablo Perel, MD, MSc, PhD; Daniel J. Piñeiro, MD; Sidney C. Smith, Jr, MD;  
8 Kathryn A. Taubert, PhD; David A. Wood, MSc; Dong Zhao, MD, PhD; William A. Zoghbi, MD

9  
10  
11 **Key Words:** AHA Scientific Statements, cardiovascular diseases, forecasting, noncommunicable  
12 disease, prevention

13

14

1 The American Heart Association and the World Heart Federation make every effort to avoid any actual or  
2 potential conflicts of interest that may arise as a result of an outside relationship or a personal,  
3 professional, or business interest of a member of the writing panel. Specifically, all members of the  
4 writing group are required to complete and submit a Disclosure Questionnaire showing all such  
5 relationships that might be perceived as real or potential conflicts of interest.

6 This document was approved by the American Heart Association Science Advisory and Coordinating  
7 Committee on December 4, 2015, and the American Heart Association Executive Committee on January  
8 19, 2016.

9 The American Heart Association requests that this document be cited as follows: Sacco RL, Roth GA,  
10 Reddy KS, Arnett DK, Bonita R, Gaziano TA, Heidenreich PA, Huffman MD, Mayosi BM, Mendis S,  
11 Murray CJL, Perel P, Piñeiro DJ, Smith S Jr, Taubert KA, Wood DA, Zhao D, Zoghbi WA. The heart of  
12 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular  
13 diseases and stroke: a modeling study. *Circulation*. 2016;133:●●●–●●●.

14 This article has been copublished in *Global Heart*.

16 Copies: This document is available on the World Wide Web sites of the American Heart Association  
17 ([my.americanheart.org](http://my.americanheart.org)) and the World Heart Federation (<http://www.world-heart-federation.org/>). A copy  
18 of the document is available at <http://my.americanheart.org/statements> by selecting either the “By Topic”  
19 link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail  
20 [kelle.ramsay@wolterskluwer.com](mailto:kelle.ramsay@wolterskluwer.com).

21 Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations.  
22 For more on AHA statements and guidelines development, visit <http://my.americanheart.org/statements>  
23 and select the “Policies and Development” link.

24 Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document  
25 are not permitted without the express permission of the American Heart Association. Instructions for  
26 obtaining permission are located at [http://www.heart.org/HEARTORG/General/Copyright-Permission-  
27 Guidelines\\_UCM\\_300404\\_Article.jsp](http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp). A link to the “Copyright Permissions Request Form” appears on  
28 the right side of the page.

29 (*Circulation*. 2016;133:000–000.)

30 © 2016 by the American Heart Association, Inc., and the World Heart Federation.

31 ***Circulation* is available at <http://circ.ahajournals.org>**

32

33

## 1 **Abstract**

2

3

4

## 5 **Background**

6           The World Health Organization (WHO), empowered by the unanimous proclamation at the  
7 United Nations High Level meeting on non-communicable diseases (NCDs) in September 2011, set  
8 a number of key targets for all nations to reach by 2025.[1] The overarching goal is to reduce the  
9 risk of premature deaths (defined as the probability of dying between the ages of 30 years and 70  
10 years of age) from NCDs (cardiovascular disease including stroke (CVD), diabetes mellitus (DM),  
11 cancer and chronic respiratory disease) by 25% by the year 2025 (referred to as “25 x 25”). The  
12 Global CVD Taskforce, comprising the World Heart Federation, American Heart Association,  
13 American College of Cardiology Foundation, European Heart Network, and European Society of  
14 Cardiology, and expanded representation from Asia, Africa, and Latin America along with global  
15 CVD experts, disseminates information and approaches to reach the WHO 2025 targets.[2-4]

16           To achieve the overarching 25 x 25 target, the WHO identified 8 targets in the  
17 prevention, control, and treatment of 6 key risk factors, as well as two health systems targets  
18 related to the use of essential medicines, technologies, and drug therapies to prevent NCDs,  
19 particularly CVDs. [5] Of the 8 targets, 6 directly align with traditional CVD and stroke risk  
20 factors: 3 risk factors (tobacco use, sodium intake, physical inactivity), 2 biological risk factors  
21 (raised blood pressure (BP), DM/obesity) and 1 management target directed at treatment of  
22 individuals at high risk of CVD. With CVD as the largest single contributor to global mortality,  
23 accounting for nearly half of the 36 million annual NCD deaths, and with a global cost of nearly  
24 US \$863 billion, achieving the global target to reduce premature NCD deaths by 25% requires  
25 that CVD and its risk factors be aggressively addressed by WHO Member States, policymakers,

1 professional organizations, public health experts, health care providers, and key stakeholders.

2 [4]

3 Although the prevalence of many of these risk factors has improved globally over the  
4 past 30 years, with the exception of DM and obesity, trends are not homogenous (Table 1).[6]  
5 Between 1990 and 2013, the age-standardized CVD death rate decreased by more than 22%  
6 for both ischemic heart disease and stroke.[7] Taking these trends into account, continued  
7 progress towards improving CV health and reducing CVD and stroke deaths is vital to reaching  
8 the overall premature NCD mortality goal by 2025, just one decade away. The aim of this paper  
9 is to investigate the potential impact of reaching selected targets in the WHO Global Monitoring  
10 Framework on the reduction of premature CVD mortality by 2025 and examine the policy  
11 implications of these predictions.

12

### 13 **Data & Methods**

14 The writing committee reflects the members of the Global CVD Taskforce. The committee  
15 engaged researchers at the Institute for Health Metrics and Evaluation (IHME), University of  
16 Washington, Seattle, WA, to develop region-specific estimates of premature cardiovascular  
17 mortality in 2025 based on various scenarios. IHME is the coordinating center for the Global Burden  
18 of Disease Study (GBD), a multinational effort to produce consistent estimates of death and  
19 disability by age, sex, and over time for all countries.[7]

20 The methods and results of this exercise have been reported in detail.[8] Data were  
21 drawn from the GBD 2013 study.[7] All estimates were produced separately for each age-sex-  
22 country-disease specific strata and then collapsed to create regional estimates. (A list of GBD  
23 2015 Geographies detailing the countries that make up “Regions” and “Super Regions” is  
24 available here:

25 [http://www.healthdata.org/sites/default/files/files/Projects/GBD/GBDRegions\\_countries.pdf](http://www.healthdata.org/sites/default/files/files/Projects/GBD/GBDRegions_countries.pdf))

1 To create a scenario in which risk factors continue the trend observed since 1990  
2 (“business as usual”), the analysis first estimated the proportion of CVD and stroke deaths in  
3 1990 and 2013 due to raised systolic BP, tobacco smoking, high body mass index (BMI) and  
4 high fasting plasma glucose, using a population attributable fraction. The effect of serum  
5 cholesterol was not included because this was not listed among the 8 primary WHO 25 x 25  
6 targets.

7 The theoretical minimum risk exposure distribution used for the GDB 2010 study was  
8 applied except for systolic BP where a theoretical minimum limit of 115 mm Hg was adopted.[9]  
9 Using the annualized rate of change between 1990 and 2013, it was assumed that the  
10 remaining deaths unattributed to these risk factors would continue their observed trend.  
11 Beginning in 2014, deaths attributable to the selected risk factors were estimated using the  
12 same population attributable fraction and risk factor exposures estimated for GBD 2013 for each  
13 age-sex-country-year projected to 2025 and the annualized rate of change between 1990 and  
14 2013. Future scenarios were developed to match four key risk factor targets for 2025: 1) no  
15 further rise in fasting plasma glucose, 2) no further rise in BMI, 3) 25% reduction in the  
16 prevalence of systolic BP >140 mm Hg via a shift in the entire population distribution of systolic  
17 BP, and 4) 30% reduction in tobacco smoking prevalence, including associated effects from  
18 second-hand smoke. For blood pressure, modeling a population-wide shift in systolic BP  
19 assumes that there will be both prevention and treatment of hypertension but no blood pressure  
20 target is specified. The analysis also estimated a scenario in which all four of these targets are  
21 achieved, adjusting for their joint effects on mortality. The impact of access to medications was  
22 not modelled because comprehensive estimates do not yet exist.

23

## 24 **Results**

### 25 **2025 Estimates of the Absolute Number of Premature Deaths from CVD**

1 Using the GBD dataset, 3 736 540 deaths (95% uncertainty interval 3 483 303, 4 009 003)  
2 from CVD occurred in 2013 among men and 2 128 134 (95% uncertainty interval 1 814 857, 2 366  
3 726) among women across the globe for those age 30 to 70 years. Table 2 shows that, globally,  
4 more men die prematurely from CVD than women, though no significant difference can be observed  
5 in sub-Saharan Africa. For 2025 given population growth and assuming trends in the selected risk  
6 factors continue, we estimate 5 009 492 premature deaths from CVD among men (95% UI (4 632  
7 942,5 389 257)) and 2 769 945 among women (95% UI (2 321 954,3 044 866)) will occur, a relative  
8 increase of 34% and 30% from 2013, respectively. Only among high-income countries, which  
9 include the United States, Canada, Australia, Western Europe, Japan, and South Korea, are there  
10 projected reductions in the absolute number of premature deaths of -19% among men and -16%  
11 among women in 2025. For the rest of world, the number of premature deaths from CVD are  
12 projected to increase from 22% in Latin America and the Caribbean to 48% in Sub-Saharan Africa  
13 among women, and from 16% in Central Europe, Eastern Europe, and Central Asia to 56% in  
14 South Asia among men, largely because of aging and growth of populations.

15 Compared to the “business as usual” estimates, the modelling showed major reductions  
16 in the number of premature deaths from CVD among men and women across all regions if the  
17 25 x 25 targets for raised BP, smoking, obesity and DM were achieved by 2025. Overall, the  
18 model projected a relative decrease of 5% among men and only a 1% increase among women  
19 in the number of premature deaths from CVD in comparison to the increases of 34% and 30% in  
20 the business as usual estimates. A significant difference between scenarios in number of  
21 premature deaths due to CVD in 2025, with no overlap of 95% uncertainty intervals, was seen  
22 globally for men and also within the region comprised of Southeast Asia, East Asia, and  
23 Oceania. Although there are projected increases from 2013 to 2025 in the absolute number of  
24 premature deaths in some regions, the 2025 estimates for the number of deaths in all regions  
25 were much improved if the risk factor targets were achieved.

1

**2 2025 Estimates of Probability of Premature Mortality from CVD**

3           The figures illustrate the global and regional projections for achieving a reduction in the  
4 probability of premature mortality from CVDs, including stroke by 2025. Figure 1 shows the  
5 global probability of premature death in women ages 30 to 70 years due to CVD using data from  
6 1990 to 2013 and projects these estimates from 2014 to 2025. Notably, recent declines in  
7 premature CVD mortality leveled off if risk factors continue the current trend. There was a small  
8 estimated reduction in premature mortality if the rise in fasting plasma glucose was halted. A  
9 similar magnitude of decline was estimated if the prevalence of smoking was reduced by 30%.  
10 Next, a more modest reduction in premature mortality would be realized by halting the rise in  
11 elevated BMI. The most robust effect from a single risk factor target being met resulted from the  
12 achievement of the BP goal of reducing the prevalence of elevated systolic BP by 25%. An  
13 important assumption of this model is that the entire population distribution of 25% was shifted  
14 leftward to achieve the target, which includes reduction of SBP both greater and less than 140  
15 mmHg. Shifts of this magnitude reflect an assumption that hypertension is both prevented, via  
16 dietary and lifestyle modification, and treated medically, via antihypertensive therapies. However  
17 two key observations of the modelling exercise are that 1) the single dominant risk factor  
18 strategy varied by region and 2) the combined strategy dominated in almost all regions. The  
19 combined scenario if all 4 risk factor targets were achieved by 2025 would result in achieving  
20 the 25x25 mortality goal for women in 2025 or shortly thereafter.

21           For men, the projections for the global probability of premature death due to CVD  
22 differed (Figure 2). First, the risk of premature death from CVD was greater for men than  
23 women, and the scenario in which current trends continue to 2025 was estimated to lead to an  
24 increased premature probability of death in 2025 compared to 2013. If either the rise in fasting  
25 plasma glucose or elevated BMI were halted, then the effects on the premature CVD mortality  
26 among men was less than that for women and no reduction in the risk of premature CVD



1 mortality by 2025 could be detected as uncertainty estimates for 2013 and 2025 overlapped.  
2 Achieving the target for smoking would have a similar impact among men and women, reducing  
3 the risk of premature mortality by approximately 4%. As among women, the BP goal also had  
4 the most profound impact on reducing premature mortality from CVD. The scenario if all 4 risk  
5 factor targets were achieved in 2025 resulted in achieving the overall goal by around 2025 for  
6 both men and women.

7         The regional variation in the probability rates for premature CVD mortality was striking,  
8 and the effects of achieving the targets are demonstrated in the figures. For high income  
9 countries among men and women (Figures 3 and 4), the 2025 premature CVD mortality target  
10 was achieved if current trends continue, but would be achieved about 5 years sooner if all 4 risk  
11 factors targets were achieved. Higher premature CVD mortality rates were estimated in Eastern  
12 Europe/Central Asia (Figure 5 and 6), Sub-Saharan Africa (Figure 7 and 8), North Africa/Middle  
13 East (Figure 9 and 10), South Asia (Figure 11 and 12), East Asia/Pacific (Figure 13 and 14),  
14 and Latin America/Caribbean (Figure 15 and 16) if current trends continue. Achieving the 4 risk  
15 factor goals by 2025, however, resulted in the overall 25 x 25 target being achieved on average  
16 in high-income regions, North Africa/Middle East, East Asia/Pacific, Latin America/Caribbean for  
17 men and women. There is substantial measurement uncertainty for these estimates,  
18 particularly in South Asia.

19

## 20 **Discussion**

21         The data illustrate the substantial variability in the global burden of premature mortality  
22 from CVD with much greater probability of cardiovascular death in low- and middle-income  
23 countries than in high- income countries. Given that raised systolic BP, smoking, overweight  
24 and obesity, and diabetes are highly prevalent in many populations and increase risk of CVD  
25 death, [10], achieving all 4 of these risk factor targets will contribute to reduction in the risk of  
26 premature mortality from CVD around the year 2025 globally. A key finding of our exercise is

1 that, globally and for almost regions, targeting all four of these risk factors leads to greater  
2 reductions in CVD death than targeting any single risk factor. However the absolute impact of  
3 the WHO 25 x 25 priority targets both in combination and independently differ significantly by  
4 world region.

5 Globally, the targets for systolic BP (reduce by 25%) and tobacco (reduce by 30%) have  
6 more substantial effects on the future scenarios compared with maintaining current levels of  
7 BMI and fasting plasma glucose. However this general observation is not true for all regions,  
8 notably high-income North America and Australasia where reductions in BMI among women  
9 dominates as a strategy. [8]. Tobacco reduction is the largest contributor to mortality reductions  
10 for women in Western Europe and high-income Asia Pacific and men in North Africa/Middle  
11 East, Central Sub-Saharan Africa, and Central Asia.[8] Because there is substantial regional  
12 variability in these projections, regions and countries will need to develop, prioritize, implement,  
13 and evaluate context-specific approaches to addressing these targets. Projections of future  
14 trends can be helpful for setting priorities in certain regions. Although the order of importance of  
15 reaching the individual risk factors varies somewhat by region, the uncertainty intervals largely  
16 overlap and the best scenario for reaching the 25 by 25 goal is to accomplish all 4 key risk  
17 factor targets.

18 Although the analyses focused on the 4 main risk factor targets, attention needs to be  
19 called to the other targets that involve improving the capacities of healthcare systems to  
20 accomplish CVD risk reduction. Two of the WHO targets that could not be modelled, include (1)  
21 50% of eligible persons receiving drug therapy and counseling including glycemic control to  
22 prevent heart attacks and strokes, and (2) 80% availability of the affordable basic technologies  
23 and essential medicines, including generics, required to treat major NCDs in both public and  
24 private facilities. It is also important to recognize in interpreting the projections that many of the  
25 8 WHO global targets are inter-dependent. For example, to achieve the 2025 WHO targets for  
26 BP and DM, major efforts to strengthen healthcare systems will be required.

1

## 2 **Policy Implications**

3       There are several policy implications of these findings. First, these results demonstrate that  
4 the greatest reduction in premature mortality can be achieved for most regions of the world by  
5 targeting a combination of risk factors. Second, more ambitious risk factor targets will be  
6 needed for fasting plasma glucose and BMI if they are to make a substantial contribution to risk  
7 reduction. A more ambitious tobacco target would also influence non-cardiovascular related  
8 deaths, such as those secondary to cancer and chronic lung disease, which were not included  
9 here.

10       In order to reduce BP, all three pillars of the global strategy for the prevention and control of  
11 NCDs will be important to address: surveillance, prevention, and health care delivered through  
12 strengthened health systems. These recommendations are described in detail in prevention  
13 guidelines produced by multiple organizations [10-15], and the WHO in its Package of Essential  
14 Non-Communicable Disease Interventions for Primary Health Care.[11] Prevention strategies  
15 and goals for reducing population mean levels of blood pressure, including the including the  
16 WHO target of a 30% relative reduction in mean population intake of salt/sodium intake, are an  
17 important component that can be provided largely by population wide interventions and policies  
18 aimed to improve healthfulness, availability, and affordability of the local and regional food  
19 supply.

20       Third, projections of future mortality based on the best available data on risk factor exposure  
21 and relative risk can serve as a useful summary measure when WHO Member States and other  
22 stakeholders are setting priorities. To achieve the 25 x 25 mortality goal (Table 3), policy  
23 decisions will need to reflect not only the cost-effectiveness of an intervention targeting a  
24 particular risk factor, but local trends in the absolute level of exposure to that risk factor.  
25 Additional investments in health surveillance will therefore be an essential component of  
26 evidence-based decision-making.[12, 13]

1

**2 Evidence-based prevention and treatment of CVD in low/middle income countries**

3           Although the model was unable to incorporate the impact of healthcare system changes  
4 in primary and secondary prevention, improving access to evidence-based approaches to the  
5 management of risk to prevent and treat CVDs will be critical to achieving the 2025 goal. Risk-  
6 based management for identification and treatment of individuals at high-risk for CVD and  
7 stroke events has been outlined by the WHO in its Package of Essential Interventions for NCDs  
8 (PEN) in low resource settings. Strategies include non-lab based CVD risk assessment,  
9 simplified treatment protocols based on drugs listed on the WHO Model List of Essential  
10 Medicines, regular audits of the adequacy of human resources, availability of equipment and  
11 laboratory reagents, adherence to clinical protocols, and maintenance of stock registers.  
12 Performance assessments show that implementation of the total-risk approach in primary health  
13 care can lead to significant improvement in blood pressure and diabetes control and to  
14 reductions in cardiovascular risk. In collaboration with ministries of health, the WHO has initiated  
15 similar projects in primary care in approximately 30 resource-constrained settings.[13]

16

**17 Strengths and Limitations**

18           The data and results from the GDB2013 study that were used provide, to date, the most  
19 robust estimates of the global and regional burden of cause-specific mortality and risk factor  
20 prevalence. Mortality data from 1990 through 2013, as well as modeled estimates of risk factor  
21 exposure, were used to create these projections. However, this analysis has limitations.

22           First, the regional figures appear to have an inflection point present at 2014. The  
23 prediction of future mortality begins in the year 2014 because mortality data was only available  
24 through 2013 at the time of the analysis. In our time series figures, we have elected to show  
25 both estimates of mortality from 1990-2013 as well as the results of our model. This inflection

1 point reflects the fact that, for the purpose of comparison, we are showing results of the  
2 GBD2013 study (in black) and result of our projection model (in colors) within the same figure.

3         Second, the projections reflect counterfactual scenarios based on the theoretical  
4 minimum risk assumed for each risk factor rather than the effect of specific interventions.  
5 Therefore these estimates reflect the combined impact of prevention and treatment, rather than  
6 being limited to treatment of individuals already at elevated risk. This assumption reflects the  
7 fact that both prevention and medical care will play an essential part in reducing the burden of  
8 CVD.

9         Third, we created models for risk factor targets a) that were limited to those agreed upon  
10 by United Nations Member States in 2013 and b) for which there was sufficient global data on  
11 exposure levels. Fourth, we restricted these analyses to reductions in premature CVD and  
12 stroke deaths. Other NCD goals, including reductions in cancer, DM, and respiratory diseases,  
13 were not estimated, but are also essential to achieving the overall NCD goal. Fifth, while joint  
14 effects were accounted for in the scenario in which all targets are met, for the BMI scenario only  
15 the direct effect of BMI was estimated on mortality, separate from its effects through BP and  
16 fasting plasma glucose. The inclusion of all the downstream effects of high BMI would have  
17 shown this strategy to have an even larger impact. Because of this decision however, the  
18 combined risk factor scenario was able to correctly account for the joint effects of the selected  
19 risk factors without overestimating the benefit of intervening on multiple metabolic risk factors.

20

## 21 **Conclusions**

22         By 2025, over 5 million premature deaths from CVD among men and 2.8 million among  
23 women are projected worldwide. Estimates of the number of people with premature death from  
24 CVD and the probability of dying in 2025 vary across the globe. These data demonstrate wide  
25 variation in estimated future trends in risk factor prevalence and premature CVD mortality that  
26 will require region-and country-specific priority setting to achieve the 25 x 25 goal. Cost-

1 effective population wide intervention strategies exist to reduce BP, tobacco, obesity, and DM  
2 but have not been widely implemented. Aggressive strategies to achieve multiple WHO targets,  
3 especially for raised blood pressure and tobacco control, will be required to meet the 25 x 25  
4 overall goal. Success is possible if the individual WHO targets are met and healthcare systems  
5 are strengthened. Achieving these goals can only be accomplished if countries and regions set  
6 priorities, implement cost-effective population wide strategies, and collaborate in public-private  
7 partnerships across multiple sectors.

8

9

10

11

## 12 **Acknowledgments**

13 Many thanks to AHA Staff members Diana Vaca McGhie and Melanie B. Turner for their  
14 contributions to the organization of the writing group and development of this manuscript.

15

16

17

1 **TABLE 1. Trends in Global Cardiovascular Health**

<i>Metric</i>	<b>Global Prevalence</b>			
	<b>1980</b>		<b>2008-2012</b>	
	<i>Men</i>	<i>Women</i>	<i>Men</i>	<i>Women</i>
<b>Tobacco use, %[14]</b>	41.2 (40.0, 42.6)	10.6 (10.2, 11.1)	31.1 (30.2, 32.0)	6.2 (6.0, 6.4)
<b>Mean SBP, mmHg[15]</b>	130.5 (127.3, 134.0)	127.2 (124.1, 130.6)	128.1 (126.7, 129.4)	124.4 (123.0, 125.9)
<b>Raised Blood Pressure, % [15]</b>	33 (28, 39)	29 (25, 34)	29 (27, 31)	25 (23,27)
<b>Phys. inactivity, %[16]</b>	N/A	N/A	19.8 (13.4-32.1)	26.8 (18.5-38.9)
<b>Obesity, %[17]</b>	4.8 (4.0, 5.7)	7.9 (6.8, 9.3)	9.8 (9.2, 10.4)	13.8 (13.1, 14.7)
<b>Diabetes, % [18]</b>	8.3 (6.5, 10.4)	7.5 (5.8, 9.6)	9.8 (8.6, 11.2)	9.2 (8.0, 10.5)

2

3

4

1 **TABLE 2. Absolute Numbers of Premature Cardiovascular Deaths in 2013 and Estimates in 2025 for Adults age 30 to 70**  
 2 **years by Super- Region**

Region	Sex	Premature Cardiovascular Deaths, 2013 (95% uncertainty interval)	Premature Cardiovascular Deaths in 2025 if Current Risk Factor Trends Continue (95% uncertainty interval)	Percentage Change in Mean Number of Deaths, 2013-2025	Premature Cardiovascular Deaths in 2025 if Risk Factor Targets are Achieved (95% uncertainty interval)	Percentage Change in Mean Number of Deaths, 2013-2025
Global	Women	2128134 (1814857,2366726)	2769945 (2321954,3044866)	30%	2159217 (1827170,2393080)	1%
Global	Men	3736540 (3483303,4009003)	5009492 (4632942,5389257)	34%*	3539896 (3316386,3804971)	-5% †
High-income	Women	164786 (148636,205642)	138356 (124811,172797)	-16%	127186 (114450,158685)	-23%
High-income	Men	362839 (342716,383975)	293289 (276513,311016)	-19%*	266359 (250676,283268)	-27%*
Central Europe, Eastern Europe, and	Women	223696 (207857,243869)	281455 (245400,302032)	26%*	227418 (195576,246731)	2%



Central Asia						
Central Europe, Eastern Europe, and Central Asia	Men	475936 (461227,490469)	553462 (531778,574519)	16%*	410376 (389566,430121)	-14%* †
Sub-Saharan Africa	Women	200443 (177291,240632)	296141 (257813,347694)	48%*	237249 (207346,282389)	18%
Sub-Saharan Africa	Men	231248 (216576,247674)	350375 (327371,374645)	52%*	289286 (269767,311035)	25%* †
North Africa and Middle East	Women	147122 (130915,163220)	194795 (173397,217242)	32%*	168165 (149818,187378)	14%
North Africa and Middle East	Men	220032 (204031,238444)	295956 (274405,319530)	35%*	247057 (228401,267836)	12% †
South Asia	Women	639046 (469768,794972)	916908 (665308,1130215)	43%	736819 (532380,910343)	15%
South Asia	Men	1097544 (904270,1317289)	1717276 (1418260,2039056)	56%*	1223642 (1020301,1457277)	11% †
Southeast Asia, East	Women	626804	788050	26%	535645	-15% †

Asia, and Oceania		(537293,720433)	(672937,899995)		(461842,609289)	
Southeast Asia, East		1163003	1568704		912417	
Asia, and Oceania	Men	(1017097,1282170)	(1373123,1748215)	35%*	(814746,1000303)	-22%* †
Latin America and Caribbean	Women	126235 (115538,147773)	154240 (140363,179209)	22%	126736 (115135,147858)	0%
Latin America and Caribbean	Men	185937 (175438,196925)	230430 (217845,242639)	24%*	190760 (180293,201545)	3% †

1 \* Indicates that 95% uncertainty interval for number of deaths in 2013 and 2025 do not overlap; † indicates that 95% uncertainty

2 interval for numbers of deaths in 2025 scenarios do not overlap

3

1 **TABLE 3. Cost Effective Population Level Strategies to Achieve Targets**

<b>WHO Risk Factor Targets and 25 x 25 Goals</b>	<b>Strategies for Population Wide Intervention</b>
<b>Tobacco</b>	
A 30% relative reduction in prevalence of current tobacco use in persons aged 15+ years	<ul style="list-style-type: none"> <li>• Higher taxes on tobacco products to reduce use and fund tobacco control programs[12, 19]</li> <li>• Smoke-free indoor workplaces, public places and public transport [12, 19, 20]</li> <li>• Mass media campaigns about the danger of tobacco and tobacco smoke including cigarette package warnings, especially those that are graphic and health related [12, 19]</li> <li>• Complete bans on all forms advertising, promotion and sponsorship of tobacco products [12, 19]</li> </ul>
<b>High Blood Pressure &amp; Sodium Reduction</b>	
<p>A 25% relative reduction in the prevalence of raised blood pressure or contain the prevalence of raised blood pressure, according to national circumstances</p> <p>A 30% relative reduction in mean population intake of salt/sodium intake</p>	<ul style="list-style-type: none"> <li>• Enact government policies to reduce sodium in packaged foods. [21, 22]</li> <li>• Mass-media campaigns and voluntary action by food industry to reduce sodium consumption. [23]</li> <li>• Implement public awareness programs on diet and physical activity [24]</li> <li>• Drug therapy (including glycemic control for diabetes mellitus and control of raised blood pressure using a total risk approach) and counselling to individuals who have had a heart attack or stroke and to persons with high risk (<math>\geq 30\%</math>) of a fatal and nonfatal cardiovascular event in the next 10 years [24]</li> </ul>

<b>Unhealthy Diet &amp; Physical Inactivity</b>	
<p>Halt the rise in diabetes and obesity</p> <p>A 10% relative reduction in prevalence of insufficient physical activity</p>	<ul style="list-style-type: none"> <li>• Replace trans fats with unsaturated fats [24]</li> <li>• Implement public awareness programs on diet and physical activity [24]</li> <li>• Fiscal methods that increase the price of foods high in saturated and industrially produced trans fats and sugar; food labelling; and marketing restrictions of unhealthy food products, especially to children and young people.[25]</li> <li>• Restrict advertising to children [24]</li> <li>• Drug therapy (including glycemic control for diabetes mellitus and control of raised blood pressure using a total risk approach) and counselling to individuals who have had a heart attack or stroke and to persons with high risk (<math>\geq 30\%</math>) of a fatal and nonfatal cardiovascular event in the next 10 years [24]</li> </ul>

- 1 Population wide interventions must be considered to impact progress towards the modifiable
- 2 risk factor targets.
- 3

## 1 REFERENCES

- 2 1. World Health Organization, Draft comprehensive global monitoring framework and targets for the  
3 prevention and control of noncommunicable diseases. Available at:  
4 [http://apps.who.int/gb/ebwha/pdf\\_files/WHA66/A66\\_8-en.pdf?ua=1](http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_8-en.pdf?ua=1). Accessed on: May 15, 2015.
- 5 2. Zoghbi WA, Duncan T, Antman E, Barbosa M, Champagne B, Chen D, Gamra H, Harold JG, Josephson S,  
6 Komajda M, Logstrup S, Mayosi BM, Mwangi J, Ralston J, Sacco RL, Sim KH, Smith SC, Vardas PE,  
7 Wood DA. Sustainable Development Goals and the future of cardiovascular health: a statement from the  
8 Global Cardiovascular Disease Taskforce. *J Am Heart Assoc*. 2014;3:e000504.
- 9 3. Smith SC, Jr., Chen D, Collins A, Harold JG, Jessup M, Josephson S, Logstrup S, Jur C, Sacco RL, Vardas  
10 PE, Wood DA, Zoghbi WA. Moving from political declaration to action on reducing the global burden of  
11 cardiovascular diseases: a statement from the global cardiovascular disease taskforce. *Circulation*.  
12 2013;128:2546-2548.
- 13 4. Smith SC, Jr., Collins A, Ferrari R, Holmes DR, Jr., Logstrup S, McGhie DV, Ralston J, Sacco RL, Stam  
14 H, Taubert K, Wood DA, Zoghbi WA. Our time: a call to save preventable death from cardiovascular  
15 disease (heart disease and stroke). *Circulation*. 2012;126:2769-2775.
- 16 5. World Health Organization, NCD Global Monitoring Framework. Available at:  
17 [http://www.who.int/nmh/global\\_monitoring\\_framework/en/](http://www.who.int/nmh/global_monitoring_framework/en/). Accessed on: May 15, 2015.
- 18 6. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and  
19 medical care to cardiovascular mortality trends. *Nat Rev Cardiol*. 2015.
- 20 7. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of  
21 death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*.  
22 2015;385:117-171.
- 23 8. Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray C. Estimates of Global and  
24 Regional Remature Cardiovascular Mortality in 2025. *Circulation*. 2015;In Press.
- 25 9. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews  
26 KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A,  
27 Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce  
28 NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B,  
29 Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson  
30 KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K,  
31 Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G,  
32 Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E,  
33 Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W,  
34 Hoek HW, Hogan A, Hosgood HD, 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn  
35 GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S,  
36 Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE,  
37 London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin  
38 R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd  
39 Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla  
40 JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD,  
41 Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA, 3rd, Powles J,  
42 Rao M, Razavi H, Rehfues EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales  
43 JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L,  
44 Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR,  
45 Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van  
46 Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA,  
47 Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P,  
48 Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk  
49 assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21  
50 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *LANCET*.  
51 2012;380:2224-2260.

- 1 10. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB.  
2 Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US  
3 adults. *JAMA*. 2012;307:1273-1283.
- 4 11. World Health Organization. Package of essential NCD interventions for primary health care: cancer,  
5 diabetes, heart disease and stroke, chronic respiratory disease. Available at:  
6 [http://www.who.int/cardiovascular\\_diseases/publications/pen2010/en/](http://www.who.int/cardiovascular_diseases/publications/pen2010/en/). Accessed on: July 23, 2015.
- 7 12. World Health Organization. From Burden to “Best Buys”: Reducing the Economic Impact of Non-  
8 Communicable Diseases in Low- and Middle-Income Countries. Available at:  
9 [http://www.who.int/nmh/publications/best\\_buys\\_summary.pdf](http://www.who.int/nmh/publications/best_buys_summary.pdf). Accessed on: June 17, 2015.
- 10 13. World Health Organization (WHO). Global status report on noncommunicable diseases 2014. Available at:  
11 [http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1). Accessed on: July 9,  
12 2015.
- 13 14. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, Wollum A, Sanman E,  
14 Wulf S, Lopez AD, Murray CJ, Gakidou E. Smoking prevalence and cigarette consumption in 187  
15 countries, 1980-2012. *JAMA*. 2014;311:183-192.
- 16 15. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS,  
17 Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating G.  
18 National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health  
19 examination surveys and epidemiological studies with 786 country-years and 5.4 million participants.  
20 *LANCET*. 2011;377:568-577.
- 21 16. World Health Organization. Global Health Observatory Data Repository. Prevalence of insufficient  
22 physical activity among adults data by WHO region. Available at:  
23 <http://apps.who.int/gho/data/view.main.2482?lang=en>. Accessed on: July 9, 2015.
- 24 17. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y,  
25 Bahalim AN, Farzadfar F, Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic  
26 Diseases Collaborating G. National, regional, and global trends in body-mass index since 1980: systematic  
27 analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million  
28 participants. *LANCET*. 2011;377:557-567.
- 29 18. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH,  
30 Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in  
31 fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination  
32 surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet*.  
33 2011;378:31-40.
- 34 19. Mozaffarian D, Afshin A, Benowitz N, Bittner V, Daniels S, Franch H, Jacobs D, Kraus W, Kris-Etherton  
35 P, Krummel D, Popkin B, Whitsel L, Zakai N. Population approaches to improve diet, physical activity,  
36 and smoking habits: a scientific statement from the American Heart Association. *Circulation*.  
37 2012;126:1514-1563.
- 38 20. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo F, Evans D, Feachem  
39 RG, Frenk J, Ghosh G, Goldie SJ, Guo Y, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK,  
40 Ncube M, Pablos-Mendez A, Reddy KS, Saxenian H, Soucat A, Ulltveit-Moe KH, Yamey G. Global health  
41 2035: a world converging within a generation. *Lancet*. 2013;382:1898-1955.
- 42 21. Pearson TA, Palaniappan LP, Artinian NT, Carnethon MR, Criqui MH, Daniels SR, Fonarow GC,  
43 Fortmann SP, Franklin BA, Galloway JM, Goff DC, Jr., Heath GW, Frank AT, Kris-Etherton PM, Labarthe  
44 DR, Murabito JM, Sacco RL, Sasson C, Turner MB, on behalf of the American Heart Association Council  
45 on E, Prevention. American Heart Association Guide for Improving Cardiovascular Health at the  
46 Community Level, 2013 Update: A Scientific Statement for Public Health Practitioners, Healthcare  
47 Providers, and Health Policy Makers. *Circulation*. 2013.
- 48 22. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and  
49 financial costs of strategies to reduce salt intake and control tobacco use. *Lancet*. 2007;370:2044-2053.
- 50 23. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets,  
51 physical inactivity, and obesity: health effects and cost-effectiveness. *Lancet*. 2010;376:1775-1784.
- 52 24. World Health Organization (WHO). Global action plan for the prevention and control of noncommunicable  
53 diseases, 2013-2020. Available at:

- 1 [http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1). Accessed on: July 9,  
2 2015.
- 3 25. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, Baugh V, Bekedam H, Billo N,  
4 Casswell S, Cecchini M, Colagiuri R, Colagiuri S, Collins T, Ebrahim S, Engelgau M, Galea G, Gaziano T,  
5 Geneau R, Haines A, Hospedales J, Jha P, Keeling A, Leeder S, Lincoln P, McKee M, Mackay J,  
6 Magnusson R, Moodie R, Mwatsama M, Nishtar S, Norrving B, Patterson D, Piot P, Ralston J, Rani M,  
7 Reddy KS, Sassi F, Sheron N, Stuckler D, Suh I, Torode J, Varghese C, Watt J. Priority actions for the non-  
8 communicable disease crisis. *Lancet*. 2011;377:1438-1447.
- 9